A study conducted over 3 periods to look at the drug in the body
Study identifier:D2350C00007
ClinicalTrials.gov identifier:NCT01225939
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Randomised, Open-label, Three-way Cross-over, Phase I Study in Healthy Subjects to Assess the Pharmacokinetics of AZD8329 after Single Doses of the Oral Solid Formulation and the Oral Solution
Medical condition
Type 2 Diabetes Mellitus
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD8329
Sex
Male
Actual Enrollment
18
Study type
Interventional
Age
18 Years - 45 Years
Date
Study Start Date: 01 Nov 2010
Primary Completion Date: 01 Dec 2010
Study Completion Date: 01 Dec 2010
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Dec 2018 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 Single Oral dose AZD8329 tablet (fasting) | Drug: AZD8329 tablet |
| Experimental: 2 Single Oral dose AZD8329 solution (fasting) | Drug: AZD8329 Solution |
| Experimental: 3 Single Oral dose AZD8329 tablet (Fed) | Drug: AZD8329 tablet |
Contacts
Investigators
Principal Investigator
J Ritter
Quintiles Drug Research Unit at Guy's Hospital
